SKF-83566 是一种有效的，可通透血脑屏障的，具有口服活性的 D1 样多巴胺受体 ( D1-like dopamine receptor) 拮抗剂，也可以作为一种较弱的竞争性拮抗剂，作用于血管 5-HT₂ 受体 (K_i =11 nM)。SKF-83566 是一种竞争性多巴胺转运蛋白 (DAT) 抑制剂，IC₅₀ 为 5.7 μM。在离体兔胸主动脉中，SKF-83566 对腺苷基环化酶 2 (AC₂) 的选择性高于对 AC₁ 和 AC₅ 的。SKF-83566 可用于研究帕金森氏症和对尼古丁渴望的缓解的相关研究。

SKF-83566 is a potent, blood-brain permeable and orally active D1-like dopamine receptor (D1DR) antagonist and a weaker competitive antagonist at the vascular 5-HT 2  receptor (K i =11 nM). SKF-83566 is a competitive DAT (dopamine transporter) inhibitor with an IC 50  of 5.7 μM. SKF-83566 also shows selective inhibition for adenylyl cyclase 2 (AC2) over AC 1 and AC 5 in the isolated rabbit thoracic aorta. SKF-83566 can be used for research of parkinson’s disease and nicotine craving alleviation.

Solid

D1 Receptor D5 Receptor

SKF-83566 (0.1 μM-10 μM) causes a concentration-dependent increase in peak evoked extracellular DA concentration ([DA]o) evoked by single-pulse stimulation, with a maximum 65% increase in peak evoked [DA]o with 5 μM. The EC50 value of this effect of SKF-83566 is 1.3 μM.
SKF-83566 inhibited [H]DA uptake with an IC50 of 5.73 μM. Moreover, SKF-83566 more potently inhibits the binding of [H]CFT, a cocaine analog, with an IC50 of 0.51 μM in [H]DA uptake and [H]CFT binding studies.
Similarly, in LLc-PK-rDAT cell, SKF-83566 also inhibits [H]CFT binding with an IC50 of 0.77 μM in LLc-PK-rDAT cell membrane preparations.
has not independently confirmed the accuracy of these methods. They are for reference only.

SKF 83566 hydrobromide (oral administration; 20 μg/mL; 7 days) alone has no effects on altering LTP (115%). However, combinnation of SKF 83566 and nicotine significantly blocks the enhancement of long-term synaptic potentiation (LTP) induced by pretreatment with nicotine (SKF 83566+nicotine+cocaine, 120%; nicotine+cocaine, 143%).
has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Powder -20°C 3 years；4°C 2 years

[1]. Yan-You Huang, et al.D1/D5 Receptors and Histone Deacetylation Mediate the Gateway Effect of LTP in Hippocampal Dentate Gyrus.
[2]. Melissa A Stouffer, et al. SKF-83566, a D1-dopamine Receptor Antagonist, Inhibits the Dopamine Transporter. J Neurochem. 2011 Sep;118(5):714-20.
[3]. E H Ohlstein, et al. SCH 23390

In Vitro: DMSO : 33.33 mg/mL (100.32 mM; Need ultrasonic)配制储备液